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Determining whether 
adsorption state is a critical 
attribute in aluminum 
adjuvanted vaccines
Garry Morefield, Ph.D.
President 
Understanding the antigen
 Biophysical characterization
 Derivative spectroscopy, intrinsic/extrinsic 
fluorescence, dynamic light scattering, static light 
scattering etc…
 pH/stability profile
 Understand how pH impacts degradation
 Excipient screening
 Sugars/sugar alcohols, surfactants, antioxidants, 
amino acids, cyclodextrins
 Accelerated Stability
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Aluminum Hydroxide Adjuvant
 Not Al(OH)3 but AlOOH (boehmite)
 Fibrous primary particles: 4.5x2.2x10 nm2
Bayerite
Gibbsite
Boehmite
Aluminum Phosphate Adjuvant
 Not AlPO4 but Al(OH)x(PO4)y
 Non-stoichiometric
 Amorphous plate like primary particles
PZC – Point of Zero Charge
 The pH at which there is no charge at the 
surface of the adjuvant.
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Aluminum Phosphate Adjuvant
 PZC inversely proportional to degree of phosphate 
substitution.
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Mechanisms of Adsorption
 Balance of forces determines adsorption
 Electrostatic attractive forces
 Occurs when the adjuvant and antigen have opposite charges
 Most frequently encountered mode of adsorption
 Ligand Exchange
 PO4 in antigen exchanges for a OH at the adjuvant surface
 Strongest mode of adsorption
 Hydrophobic interactions
 Other forces
 Hydrogen bonding
 Van der Waals
Group A Strep vaccine background
 Streptococcus pyogenes is a Gram-positive bacterium 
that causes a wide variety of diseases such as strep 
throat, scarlet fever, necrotizing fasciitis, streptococcal 
toxic shock syndrome, and impetigo. These diseases are 
generally referred to as Group A Streptococcal (GAS) 
diseases.
 VaxForm is developing a vaccine targeting GAS infection 
consisting of a recombinant fusion protein comprising 
genetically mutated SpeA and SpeB virulence factors.
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Adjuvant Surface Evaluation
 Antigen characterization determined the antigen was 
stable at pH 8 and had a negative charge.
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Typically have stability 
issues in this region
More stable 
adsorption
Difficult to control 
between batches
Non-adsorbed
Formulation Comparison In Vivo
 BALB/c mice administered vaccine on 
days 0 and 14.
 5, 2, or 0.4 mg dose of antigen
 IM administration
 Sera collected on day 28.
 Neutralizing antibody evaluated.
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Formulation Adsorption
 Adsorption remained within target through the duration 
of the study.
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Development of a recombinant fusion protein 
vaccine formulation to protect against 
Streptococcus pyogenes. G Morefield, G 
Touhey, F Lu, A Dunham, and H HogenEsch. 
Vaccine 32:3810-3815, 2014.
Considerations once a formulation has 
been determined
 Adsorption stability
 Impact of microenvironment pH
 Surface pH can vary by up to 2 pH units from 
that of the bulk
 Stability assay development
 Can antigen stability be monitored in vitro on 
the adjuvant surface?
 Impact of adjuvant lot to lot variability
13
Questions?
 VaxForm
 Elodie Burlet, Graham Touhey, Kim Williams, 
Dan Paez
 Purdue University
 Harm HogenEsch, Anisa Dunham, Fangjia Lu
 DoD grant W81XWH-12-C-0183
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